ANTIHYPERTENSIVE THERAPY AND DYSLIPIDEMIA. SIAMESE TREATMENT!

Objective: Cardiovascular diseases are the leading cause of morbidity and mortality in industrialized countries. This was a retrospective observational study, evaluating clinical outcomes, metabolic consequences and survival rate resulting from prolonged intermediate-intensity statin therapy dosages for primary prevention In this study we set out to analyze the importance of the repercussions of synergies anti-hypertension therapies in conditioning the results in the dyslipidemia profile. Design and method: Among the 1677 patients who attended a medical consultation between January 1995 and May 2015, a population-based sample of 516 patients were included in the study. After signing the informed consent, data were collected from the patients’ medical charts. Selection criteria: 1) patients who had at least two personal and/or family-related CVRF: 2) regularly attended a quarterly consultation for a minimum of two years, 3) performed an annual biochemical examination, including cardiovascular complementary exams with clinical evaluation Results: Statins, angiotensin converting enzyme inhibitors (ACEI), ARB-II, oral antidiabetics (OAD), antiplatelets, calcium channels antagonists (CCA) and allopurinol were selected for the initial regression model, due to their clinical influence on LDLc variation (Table 3). Again, only patients under treatment and who have not died during the study were considered in this analysis. Results from the optimized final model (Table 2, supplemental material) revealed that LDLc decreased in patients taking statins 51.780 mg/dL more than in those who did not, after adjustment for ACEI and ARB-II. LDLc decreased in patients taking ACEI 12.563 mg/dL more than in those who did not, after adjustment for statins and ARB-II. Moreover, LDLc decreased in patients taking ARB-II 8.221 mg/dL more than in those who did not, after adjustment for statins and ACEI. Conclusions: This study shows the benefits of an early and continued therapy with intermediate-intensity statins for primary prevention and highlights the synergic effects with other drugs for treatment of hypertension such as ACEI, ARB-II, CCA,